A 3D human heart lit by red rim light — health coverage from STAT
Adobe

Next week, the biopharma world will see eagerly awaited results from a trial that could shape care for patients with an increasingly common heart condition — and determine which companies stand to reap billions. 

The trial of vutrisiran, from Alnylam Pharmaceuticals, was already announced as positive, with the drug successfully cutting the risk of death and cardiovascular complications in patients with the disease, called transthyretin amyloid cardiomyopathy, or ATTR-CM. Given the strong data, the RNA-interference therapy is expected to win regulatory approval.

advertisement

But Alnylam’s drug is not the only option for patients. Pfizer has a pair of competing therapies, and BridgeBio has one nearing approval. Investors and cardiologists have been anticipating the full results of Alnylam’s HELIOS-B trial, which are scheduled to be presented next Friday, Aug. 30, in London at the annual meeting of the European Society of Cardiology. 

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe